Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease

Gut

Volumn 42, Issue 4, 1998, Pages 493-496

  Gross, V ^a   Andus, T ^a   Ecker, K W ^c   Raedler, A ^d   Loeschke, K ^e   Plauth, M ^f   Rasenack, J ^g   Weber, A ^h   Gierend, M ^h   Ewe, K ^b   Scholmerich J ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d UNIVERSITY OF HAMBURG   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

^h Medicomp   (Germany)

Author keywords

Budesonide; Crohn's disease; Maintenance of remission

Indexed keywords

BUDESONIDE; EUDRAGIT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION;

EID: 7144264393     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.42.4.493     Document Type: Article

References (23)

1. Summers RW, Switz DM, Sessions JT, et al. National cooperative Crohn's disease study: results of drug treatment. Gastroenterology 1979;77:847-69.
2. Malchow H, Ewe K, Brandes JW, et al. European cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66.
3. Lochs H, Steinhardt HJ, Klaus-Wentz B, et al. Comparison of enterai nutrition and drug treatment in active Crohn's disease. Results of the European cooperative Crohn's disease study IV.Gastroenterology 1991;101:881-8.
4. Wolman SL, Greenberg GR. Oral budesonide in active Crohn's disease: an initial experience [abstract]. Gastroenterology 1991;100:A263.
5. Löfberg R, Danielsson A, Salde L. Oral budesonide in active Crohn's disease. Aliment Pharmacol Ther 1991;7:611-16.
6. Roth M, Gross V, Ueberschaer B, et al. Treatment of active Crohn's disease with an oral slow-release budesonide formulation. Am J Gastroenterol 1993;88:968-9.
7. Caesar I, Gross V, Roth M, et al, and members of the German Budesonide Study Group. Treatment of active Crohn's ileocolitis with oral pH-modified budesonide. Z Gastroenterol 1995;35:237-50.
8. Andus T, Gross V, Caesar I, et al, and the German Budesonide Study Group. Replacement of conventional steroids by budesonide in active or inactive Crohn's disease. Interim analysis of an open prospective, multicenter trial [abstract]. Gastroenterology 1995;108(suppl):A771.
9. Rutgeerts P, Lötberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-5.
10. Greenberg GR, Feagan BD, Martin F, et al. Oral budesonide for active Crohn's disease. N Engl J Med 1994;331:836-42.
11. Campieri M, Ferguson A, Doe W, et al. Oral budesonide competes favourably with prednisolone in active Crohn's disease. Gastroenterology 1995;108:A790.
12. Gross V, Andus T, Caesar I, et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease [abstract]. Eur J Gastroenterology Hepatol 1996;8:905-9.
13. Landi B, N'guyen A, Cortot A, et al. Endoscopic monitoring of Crohn's disease: a prospective, randomized clinical trial. Gastroenterology 1992;102:1647-53.
14. Modigliani R, Colombel JF, Dupas J-L, et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Gastroenterology 1996;110:688-93.
15. Steinhart AH, Hemphill D, Greenberg GR. Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis. Am J Gastroenterol 1994;89:2116-24.
16. Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. Gastroenteroloagy 1993; 104:435-9.
17. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981.
18. Ewe K, Press AG, Singe CC, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993;105:367-72.
19. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995;122:132-42.
20. Candy S, Wright J, Gerber M, et. al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37;674-8.
21. Löfberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and in ileocaecal Crohn's disease. A placebo controlled one year study. Gut 1996;39:82-6.
22. Greenberg GR, Feagan BG, Martin F, et al, and the Canadian Inflammatory Bowel Disease Study Group. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled dose-ranging study. Gastroenterology 1996;110:45-51.
23. Schreiber S, Schottelius A, Baumann J, et al. Immunopharmacology of budesonide induced inhibition of pro-inflammatory cytokine secretion by IBD mononuclear phagocytes [abstract]. Gastroenterology 1996;110:A1011.